Patheon NV (NASDAQ: PTHN) and Juniper Pharmaceuticals (NASDAQ:JNP) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitabiliy.

Analyst Recommendations

This is a summary of recent ratings for Patheon NV and Juniper Pharmaceuticals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Patheon NV 0 7 4 0 2.36
Juniper Pharmaceuticals 0 2 2 0 2.50

Patheon NV presently has a consensus target price of $32.45, suggesting a potential downside of 7.10%. Juniper Pharmaceuticals has a consensus target price of $17.58, suggesting a potential upside of 262.54%. Given Juniper Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Juniper Pharmaceuticals is more favorable than Patheon NV.

Valuation and Earnings

This table compares Patheon NV and Juniper Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Patheon NV $1.93 billion 2.63 $352.50 million N/A N/A
Juniper Pharmaceuticals $55.34 million 0.95 $7.46 million $0.61 7.95

Patheon NV has higher revenue and earnings than Juniper Pharmaceuticals.

Institutional & Insider Ownership

34.3% of Juniper Pharmaceuticals shares are owned by institutional investors. 11.6% of Juniper Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares Patheon NV and Juniper Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Patheon NV 5.71% N/A 4.09%
Juniper Pharmaceuticals 12.00% 19.03% 12.65%


Juniper Pharmaceuticals beats Patheon NV on 7 of the 12 factors compared between the two stocks.

About Patheon NV

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

Receive News & Stock Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related stocks with our FREE daily email newsletter.